Inpact of bisoprolol therapy on brain perfusion in patients with metabolic syndrome

In the metabolic syndrome, the main cause of death is cardiovascular events due to the high rate of damage to target organs, lb treat patients with the metabolic syndrome, it is necessary to more thoroughly choose drugs or their combination to prevent adverse metabolic effects and at the same time to adequately monitor blood pressure. It has been long considered that β-blockers exert a negative effect on lipid and carbohydrate metabolism and they arc able to deteriorate brain perfusion in patients with arterial hypertension. This study was undertaken to evaluate the effects of bisoprolol on the daily BP profile, lipid and carbohydrate metabolism and brain perfusion in patients with the metabolic syndrome and hypertension.

β-адреноблокатры, hypertension, metabolic syndrome, β-adrenoblockers, bisoprolol, carbohydrate metabolism, lipid metabolism: brain perfusion, single-photon emission computed tomography

1. Bertel O., Marx B.E., Conen D. Effects of antihypertensive treatment on cerebral perfusion. Am J Med. 1987 Mar 30;82 (3B): 29-36.

2. Meyer J.S., Rogers R.L., Mortel K.F. Prospective analysis of long term control of mild hypertension on cerebral blood flow. Stroke. 1985 Nov-Dec; 16 (6): 985-90.

3. Hares P., James I.M., Griffith D. The effect of acebutolol on the cerebral circulation of man. Br J Clin Pharmacol. 1977 Jun; 4 (3): 373-5.

4. Fuijshima M., Ihayashi S., Fugii K. et al. Effects of lonf-term antihypertensive treatment on cerebral thalamic and cerebral blood flow in spontaneously hypertensive rats SHR. Stroke 1986; 17-5.

5. Fogari R., Zoppi A., Corradi L., Preti P., Mugellini A., Lusardi P. Beta-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol. 1999 Apr; 33 (4): 534-9.

6. Vulpis V., Antonacci A., Prandi P., Bokor D., Pirrelli A. The effects of bisoprolol and atenolol on glucose metabolism in hypertensive patients with non-insulin-dependent diabetes mellitus. Minerva Med. 1991 Apr; 82 (4): 189-93.

7. Frithz G. Influence on plasma-insulin and blood-glucose by treatment with disoprolol in hypertensive, non-diabetic patients. J Clin Basic Cardiol 2001; 4: 229-30.

8. Fogari R., Zoppi A., Tettamanti F., Poletti L., Lazzari P., Pasotti C., Corradi L. Beta-blocker effects on plasma lipids in antihypertensive therapy: importance of the duration of treatment and the lipid status before treatment. J Cardiovasc Pharmacol. 1990; 16 Suppl 5: S76-80.

9. Chang P.C., van Veen S., Vermeij P., van Brummelen P. Double-blind comparison of the beta 1-selectivity of single doses of bisoprolol and atenolol. J Cardiovasc Pharmacol. 1986; 8 Suppl 11: S58-60.

10. Asmar R.G., Kerihuel J.C., Girerd X.J., Safar M.E. Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension. Am J Cardiol. 1991 Jul 1;68 (1): 61-4.

11. Frithz G., Weiner L. Effects of bisoprolol on blood pressure, serum lipids and HDL-cholesterol in essential hypertension. Eur J Clin Pharmacol. 1987; 32 (1): 77-80.

12. Haneda T., Ido A., Fujikane T., Tanaka H., Tanazawa S., Morimoto H., Kato J., Kanaya K., Honda H., Sakai H., Akita N., Hirayama T., Onodera S., Kikuchi K. Effect of bisoprolol, a beta 1-selective beta-blocker, on lipid and glucose metabolism and quality of life in elderly patients with essential hypertension. Nihon Ronen Igakkai Zasshi. 1998 Jan; 35 (1): 33-8.

13. Janka H.U., Ziegler A.G., Disselhoff G., Mehnert H. Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics. J Cardiovasc Pharmacol. 1986; 8 Suppl 11: S96-9.

14. Dominguex L.J., Barbagallo M., Jacoher S.J., Jacobs D.B., Sowers J.R. Bisoprolol and captopril effects on insulin receptor tyrosine kinase activity in essential hypertension. Am J Hypertens. 1997 Dec;10 (12 Pt 1): 1349-55.

15. Верещагин Н.В., Борисенко В.В., Власенко В.В. Мозговое кровообращение. Современные методы исследования в клинической неврологии.

16. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998 Sep 12; 317 (7160): 713-20.